Semaglutide The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN-6) trial (2016) showed a 26% reduction in MACE (HR 0.74, 95% CI 0.580.95) in subcutaneous semaglutide (0.5 or 1.0 mg weekly) in 3,297 T2DM patients [7]
Total daily dose: Weeks 14 at 330 mcg total , then Weeks 58 at 500 mcg total , once daily (or 5 days on, 2 off)
Major health insurers and Pharma benefit managers often weigh ICER findings when determining tier placement or granting prior authorization
Those who suffer from fine lines or wrinkles and want to improve skin elasticity
As we know, the GLP1a drugs bind to and activate the GLP1 receptor, causing a range of effects, including increased insulin secretion, glucagon suppression and slowed gastric emptying
We pride ourselves on a comfortable and welcoming environment, supported by a state-of-the-art facility furnished with cutting-edge technology to ensure optimal treatment results